The ENDOMIX project explores how mixtures of endocrine-disrupting chemicals (EDCs) affect health across the human lifespan, with a focus on immune system impacts.
Using human biomonitoring data from European cohorts, the project combines pioneering methodologies ranging from high-throughput in vitro bioassays, sophisticated organoid and co-culture systems to in vivo models to uncover mechanisms and long-term effects of EDC exposure. It aims to identify measurable biomarkers and exposure patterns linked to disease, strengthen causal links through a weight-of-evidence approach, and use knowledge graphs to support rapid risk assessments. The knowledge generated by ENDOMIX will provide an evidence base for policy-making and also reach people of all ages to raise awareness of the risks of EDC exposure and encourage health-promoting behaviours.
Since its launch in January 2024, the project has made significant strides in uncovering how chemical mixtures affect the immune system and overall human health. By analysing data from over 83,000 chemicals, ENDOMIX researchers have identified more than 7,000 chemicals with potential immunomodulatory properties.
These insights are instrumental in shaping the next generation of diagnostic tools and testing methods to evaluate the combined effects of chemical exposures. ENDOMIX places a strong emphasis on real-world exposure scenarios, ensuring that its findings are directly applicable to public health policy and regulatory frameworks.
Through innovative high-throughput screening and advanced modeling techniques, the project is paving the way for more effective health risk assessment and protective strategies against harmful chemical exposures. To date, ENDOMIX has released eight public deliverables, published three scientific papers, and made its data on the mixture prioritisation openly available on Zenodo.
Stay tuned about ENDOMIX and its research activities by signing up for our newsletter and the bottom of our home page.
